Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heidel

Showing results (681-690 of 715) with videos related to

Pageof 72
Sort By:
British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2025
Prodrug activation in malaria parasites mediated by an imported erythrocyte esterase, acylpeptide hydrolase (APEH)Sesh A Sundararaman, Justin J Miller, Ellora C Daley, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2024
Prodrug activation in malaria parasites mediated by an imported erythrocyte esterase, acylpeptide hydrolase (APEH)S A Sundararaman, J J Miller, E C Daley, et al.
Annals of Hematology|December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinibMassimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Cancer|April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosisFrancesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Cancers|September 27, 2025
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity TherapyKatja Krüger, Razif Gabdoulline, Martin Wichmann, et al.
Leukemia|February 9, 2026
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemiaRabea Mecklenbrauck, Angela Villaverde Ramiro, Eric Sträng, et al.
BMJ Open|February 13, 2020
Hospital-wide ELectronic medical record evaluated computerised decision support system to improve outcomes of Patients with staphylococcal bloodstream infection (HELP): study protocol for a multicentre stepped-wedge cluster randomised trialStefan Hagel, Julia Gantner, Cord Spreckelsen, et al.
Nature|November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasmsAshok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Pageof 72

Showing results (681-690 of 715) with videos related to

Sort By:
Pageof 72
British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2025
Prodrug activation in malaria parasites mediated by an imported erythrocyte esterase, acylpeptide hydrolase (APEH)Sesh A Sundararaman, Justin J Miller, Ellora C Daley, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2024
Prodrug activation in malaria parasites mediated by an imported erythrocyte esterase, acylpeptide hydrolase (APEH)S A Sundararaman, J J Miller, E C Daley, et al.
Annals of Hematology|December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinibMassimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Cancer|April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosisFrancesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Cancers|September 27, 2025
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity TherapyKatja Krüger, Razif Gabdoulline, Martin Wichmann, et al.
Leukemia|February 9, 2026
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemiaRabea Mecklenbrauck, Angela Villaverde Ramiro, Eric Sträng, et al.
BMJ Open|February 13, 2020
Hospital-wide ELectronic medical record evaluated computerised decision support system to improve outcomes of Patients with staphylococcal bloodstream infection (HELP): study protocol for a multicentre stepped-wedge cluster randomised trialStefan Hagel, Julia Gantner, Cord Spreckelsen, et al.
Nature|November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasmsAshok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Pageof 72